Use of ultra-low dose CT versus standard-dose CT to quantify emphysema.
Ultra-low dose CT (ULDCT) with and without iterative reconstruction (IR) can substitute for standard-low dose (SDCT) when quantifying emphysema, according to a study published in the American Journal of Roentgenology.
Researchers from Japan performed a retrospective study to evaluate the agreement between SDCT and ULDCT findings among 50 patients diagnosed with emphysema, with respect to emphysema quantification. ULDCT images were reconstructed with and without IR. Adaptive iterative dose reduction with 3D processing was used for IR.
All patients underwent SDCT (tube current: 250 mA) and ULDCT (tube current: 10 mA) and ULDCT with IR was used for emphysema quantification. The low-attenuation volume percentage (LAV%) in the lungs at four thresholds (−970, −950, −930, and −910 HU), mean lung attenuation, and total lung volume were computed. Concordance correlation coefficients (CCC) were used to assess the agreement of emphysema quantification between SDCT and ULDCT.
The results showed that the LAV% CCC values were 0.310–0.789 between SDCT and ULDCT without IR and 0.934–0.966 between SDCT and ULDCT with IR. The agreement of LAV% improved when IR was used for ULDCT. The mean lung attenuation CCC value between SDCT and ULDCT without IR was substantial (0.957), whereas that between SDCT and ULDCT with IR was poor (0.890). The total lung volume CCC values were substantial (0.982 with IR, 0.983 without IR).
The researchers concluded that using ULDCT with and without IR can substitute for SDCT in emphysema quantification.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.